| Literature DB >> 35009103 |
Ioana-Ecaterina Pralea1, Radu-Cristian Moldovan1, Adrian-Bogdan Țigu2, Alina-Maria Petrache1, Simona-Codruța Hegheș3, Monica Mitoi4, Gina Cogălniceanu4, Cristina-Adela Iuga1,3.
Abstract
Leontopodium alpinum Cass. (edelweiss) is recognized as a frequent constituent of anti-aging skin care products, providing increased antioxidant and anti-inflammatory defense. Considering the growing demand and the protected status of edelweiss in many countries, alternative methods of production have been developed, one of them being callus culturing. This study reports the phytochemical composition of a methanolic extract of L. alpinum callus cultures, characterized by liquid chromatography coupled to ion-mobility high resolution mass spectrometry (UPLC/IM-HRMS). The methanolic extract exhibited strong free radical scavenging activity (122.19 ± 7.28 mg AAE/g dw), while the quantitative evaluation revealed that four major constituents (phenylpropanoid derivatives) represent 57.13% (m/m) of the extract. Consequently, a screening of antiproliferative effects was performed on ten cancer cell lines, representative of prostate, colon, lung and breast cancer, showing inhibition of colony formation in all cases. These results provide a comprehensive phytochemical characterization of L. alpinum callus cultures using advanced IM-HRMS, while the in vitro explorations confirmed the potent antioxidant properties of edelweiss which are worth exploring further in cancer prevention.Entities:
Keywords: antioxidants; callus cultures; edelweiss; ion-mobility mass spectrometry; phytochemical characterization
Year: 2021 PMID: 35009103 PMCID: PMC8747157 DOI: 10.3390/plants11010100
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Base peak chromatogram of L. alpinum callus cultures’ methanolic extract. Peak numbers correspond to the compounds from Table 1.
Compound identifications obtained after LC-IM-MS analysis of L. alpinum callus cultures.
| Peak | Rt | ΔmDa | Formula [M − H]− | Major Fragments | CCS (Å2) | Tentative Identification | Identif. | ||
|---|---|---|---|---|---|---|---|---|---|
|
| 0.87 | 191.0561 | 191.0556 | 0.6 | C7H11O6 | - | 113.55 | Quinic acid | 2 |
|
| 0.93 | 191.0195 | 191.0192 | 0.3 | C6H7O7 | 111.0085 | 113.23 | Glucaric acid—(H2O) | 2 |
|
| 1.15 | 191.0195 | 191.0192 | 0.3 | C6H7O7 | 111.0086 | 113.25 | Glucaric acid isomer—(H2O) | 2 |
|
| 2.18 | 315.0722 | 315.0716 | 0.6 | C13H15O9 | 152.0109, 108.0214 | 161.99 | Dihydroxybenzoic acid glucoside | 2 |
|
| 3.37 | 353.0886 | 353.0873 | 1.3 | C16H17O9 | 191.0561 | 171.81 | Chlorogenic acid ** | 1 |
|
| 3.82 | 533.0943 | 533.0931 | 1.2 | C24H21O14 | 371.0618, 191.0195 | 206.43 | Di-caffeoyl-glucaric acid isomer | 2 |
|
| 4.17 | 533.0943 | 533.0931 | 1.2 | C24H21O14 | 371.0617, 191.0195 | 207.06 | Di-caffeoyl-glucaric acid isomer | 2 |
|
| 4.70 | 533.0941 | 533.0931 | 1.0 | C24H21O14 | 371.0541, 191.0195 | 209.91 | Di-caffeoyl-glucaric acid isomer | 2 |
|
| 4.74 | 441.1396 | - | - | - | 431.1111, 395.1347, 233.0822 | 196.85 | Unidentified | - |
|
| 5.13 | 441.1396 | - | - | - | 431.1111, 395.1353, 233.0823 | 194.03 | Unidentified | - |
|
| 5.54 | 447.1333 | - | - | - | 267.0688, 187.1081, 132.0561 | 190.84 | Unidentified | - |
|
| 5.74 | 515.1194 | 515.1190 | 0.4 | C25H23O12 | 353.0869, 191.0540 | 207.25 | Di-caffeoyl quinic acid isomer | 2 |
|
| 5.82 | 695.1250 | 695.1248 | 0.2 | C33H27O17 | 533.094, 371.0616, 209.0295 | 235.82 | Leontopodic acid B ** | 1 |
|
| 5.89 | 515.1192 | 515.1190 | 0.2 | C25H23O12 | 353.0884, 191.0559 | 206.29 | 3-5-Dicaffeoylquinic | 1 |
|
| 6.24 | 695.1256 | 695.1248 | 0.8 | C33H27O17 | 533.0953, 371.0609, 209.0291 | 237.11 | Leontopodic acid B | 2 |
|
| 6.27 | 515.1191 | 515.1190 | 0.1 | C25H23O12 | 353.0869 | 210.01 | Di-caffeoylquinic acid | 2 |
|
| 6.43 | 781.1635 | 781.1616 | 1.9 | C37H33O19 | 619.1305, 457.0991, 295.0668, 191.0195, 161.0241 | 252.37 | Leontopodic acid A ** | 1 |
|
| 6.55 | 781.1635 | 781.1616 | 1.9 | C37H33O19 | 619.1305, 457.0991, 295.0668, 191.0195, 161.0241 | 254.65 | Leontopodic acid A | 2 |
|
| 6.63 | 687.2325 | - | - | - | 643.2434, 625.2344, 525.1796 | 245.99 | Unidentified | - |
|
| 6.70 | 285.0806 | - | - | - | 187.1138, 132.0585 | 159.91 | Unidentified | - |
|
| 6.94 | 689.2512 | - | - | - | 645.2613, 627.2507 | 246.59 | Unidentified | - |
|
| 6.96 | 689.2524 | - | - | - | 645.2619, 627.2514 | 245.98 | Unidentified | - |
|
| 7.09 | 311.0596 | - | - | - | 231.1030, 187.1129, 132.0581 | 167.45 | Unidentified | - |
|
| 7.33 | 857.1572 | 857.1565 | 0.7 | C42H33O22 | 695.1257, 533.0953, 371.0629, 209.0308, 191.0201 | 261.88 | Tetra-caffeoyl glucaric acid | 2 |
|
| 7.41 | 607.2763 | - | - | 563.2867, 463.2362, 301.1818, 209.0307 | 242.57 | Unidentified | - | |
|
| 7.55 | 867.1991 | 867.1984 | 0.7 | C41H39O21 | 705.1687, 543.1373, 381.1049, 277.0576, 209.0280, 191.0202 | 270.18 | Penta-substituted | 3 |
|
| 7.84 | 283.0646 | - | - | - | 203.1081, 148.0531 | 156.10 | Unidentified | - |
* Identification level confidence (as described by Schrimpe-Rutledge et al. [21]); ** Identified by comparison with reference standards.
Quantitative determination of the major constituents.
| Compound | µg/mg of Dry | mg/g of Dry-Frozen |
|---|---|---|
|
| 178.6 | 47.15 |
|
| 219.9 | 58.05 |
|
| 99.1 | 26.16 |
|
| 73.7 | 19.45 |
|
|
|
|
Figure 2Effects of L. alpinum extract on cell viability. The panel of cell lines includes breast, prostate, lung and colon cancer representatives, as well as human fibroblast BJ. Cells were exposed to the indicated concentrations of L. alpinum extract for 48 h. Untreated cells (blank control) were exposed only to culture media while positive controls were represented by cells treated with 100% DMSO. Cell viabilities are expressed as percentage of control (set as 100%) and represented as mean ± SEM (n = 3). Data was analyzed by one-way ANOVA followed by Dunnett’s multiple-comparison test. The asterisks *, **, *** and **** indicate significant difference at p < 0.05, p < 0.01, p < 0.001 and p < 0.0001, respectively, compared to corresponding control.
Summary of the in vitro effects of Leontopodium alpinum treatment on the investigated cell lines.
| Cancer Type | Prostate | Colon | Lung | Breast | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| BJ | 22RV1 | LNCAP | DLD-1 | HCT-116 | H1792 | SK-MES-1 | MDA-MB-231 | MDA-MB-468 | HS578T | MCF-7 | |
|
| + | n.c. | n.c. | ++ | ++ | + | +++ | +++ | ++ | ++ | n.c. | |
|
| Cell population reduction | ++ | + | - | +++ | +++ | ++ | + | +++ | - | + | - |
| Nuclear fragmentation | - | +++ | + | ++ | ++ | + | - | ++ | + | + | ++ | |
| Cytoskeleton fragmentation | - | ++ | ++ | ++ | - | +++ | + | + | + | ++ | ++ | |
| Rounding of cells | - | ++ | ++ | ++ | +++ | +++ | +++ | - | - | ++ | + | |
| Multi-lobed nuclei | - | + | - | - | + | - | + | - | - | + | - | |
|
| n.d. | + | + | + | + | + | + | + | + | + | + | |
n.c.—no correlation; “+”—small effect; “++”—medium effect; “+++”—considerable effect; “-”—effect absent; n.d.—no data.
Figure 3Colony assay evaluation on ten cancer cell lines. (Statistical analysis: unpaired t-test was applied to determine significant differences in colony numbers. * p < 0.05, ** p < 0.01).